The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

The overwhelming federal nature of this subject is apparent,” the lawsuit alleges. “States are not free to tinker with ...

Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III trials. The ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

The monoclonal antibody (mAb) helped maintain safe platelet levels for a prolonged period, reducing patient reliance on ...

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Novartis (LON:0QLR) (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, ...

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...